BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008;18:1430-1437. [PMID: 18500507 DOI: 10.1007/s11695-008-9506-y] [Cited by in Crossref: 192] [Cited by in F6Publishing: 178] [Article Influence: 13.7] [Reference Citation Analysis]
Number Citing Articles
1 Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305-315. [PMID: 29154965 DOI: 10.1016/j.jhep.2017.11.013] [Cited by in Crossref: 190] [Cited by in F6Publishing: 176] [Article Influence: 38.0] [Reference Citation Analysis]
2 Okada LSDRR, Oliveira CP, Stefano JT, Nogueira MA, Silva IDCGD, Cordeiro FB, Alves VAF, Torrinhas RS, Carrilho FJ, Puri P, Waitzberg DL. Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH – Proteomic and lipidomic insight. Clinical Nutrition 2018;37:1474-84. [DOI: 10.1016/j.clnu.2017.08.031] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
3 Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH — current progress and future promise. Nat Rev Gastroenterol Hepatol 2018;15:461-78. [DOI: 10.1038/s41575-018-0014-9] [Cited by in Crossref: 153] [Cited by in F6Publishing: 144] [Article Influence: 38.3] [Reference Citation Analysis]
4 Cengiz M, Ozenirler S, Kocabiyik M. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis: . European Journal of Gastroenterology & Hepatology 2016;28:57-63. [DOI: 10.1097/meg.0000000000000502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Tran A, Gual P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin Res Hepatol Gastroenterol. 2013;37:17-29. [PMID: 23347840 DOI: 10.1016/j.clinre.2012.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
6 Denk G, Omary AJ, Reiter FP, Hohenester S, Wimmer R, Holdenrieder S, Rust C. Soluble intracellular adhesion molecule, M30 and M65 as serum markers of disease activity and prognosis in cholestatic liver diseases. Hepatol Res. 2014;44:1286-1298. [PMID: 24451045 DOI: 10.1111/hepr.12304] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
7 Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis. 2009;13:249-266. [PMID: 19442917 DOI: 10.1016/j.cld.2009.02.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
8 Kitade M, Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Yamazaki M, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Sawai M, Yoshida M, Morioka C, Tsujimoto T, Kawaratani H, Fukui H. Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15(41): 5193-5199 [PMID: 19891019 DOI: 10.3748/wjg.15.5193] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
9 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. [Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. Pathologe. 2010;31:225-237. [PMID: 20221762 DOI: 10.1007/s00292-010-1298-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
10 Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009;2009:831670. [PMID: 19753129 DOI: 10.1155/2009/831670] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
11 Jazwinski AB, Thompson AJ, Clark PJ, Naggie S, Tillmann HL, Patel K. Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. J Viral Hepat. 2012;19:278-282. [PMID: 22404726 DOI: 10.1111/j.1365-2893.2011.01546.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
12 Polyzos SA, Kountouras J, Slavakis A, Zafeiriadou E, Patsiaoura K, Katsiki E, Zavos C, Papatheodorou A, Terpos E. A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. Biomarkers 2013;18:607-13. [DOI: 10.3109/1354750x.2013.838305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
13 Okhovatian F, Rezaei Tavirani M, Rostami-Nejad M, Rezaei Tavirani S. Protein-Protein Interaction Network Analysis Revealed a New Prospective of Posttraumatic Stress Disorder. Galen Med J 2018;7:e1137. [PMID: 34466439 DOI: 10.22086/gmj.v0i0.1137] [Reference Citation Analysis]
14 Rosato V, Masarone M, Aglitti A, Persico M. The diagnostic conundrum in non-alcoholic fatty liver disease. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00018] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19-31. [PMID: 24274862 DOI: 10.1016/j.cld.2013.09.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
16 Leite NC, Salles GF, Cardoso CR, Villela-Nogueira CA. Serum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis. Hepatol Res 2013;43:508-15. [PMID: 23067270 DOI: 10.1111/j.1872-034X.2012.01106.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
17 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch 2011;458:511-23. [PMID: 21442288 DOI: 10.1007/s00428-011-1066-1] [Reference Citation Analysis]
18 Khan M, Joseph F. Adipose tissue and adipokines: the association with and application of adipokines in obesity. Scientifica (Cairo) 2014;2014:328592. [PMID: 25309775 DOI: 10.1155/2014/328592] [Cited by in Crossref: 22] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
19 Tincopa MA. Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00177. [PMID: 33102798 DOI: 10.1002/edm2.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Arora A, Sharma P. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:145-155. [PMID: 25755423 DOI: 10.1016/s0973-6883(12)60103-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
21 Darweesh SK, AbdElAziz RA, Abd-ElFatah DS, AbdElazim NA, Fathi SA, Attia D, AbdAllah M. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients. Eur J Gastroenterol Hepatol. 2019;31:633-641. [PMID: 30839434 DOI: 10.1097/meg.0000000000001385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
22 Yilmaz Y. Cytokeratins in hepatitis. Clin Chim Acta 2011;412:2031-6. [PMID: 21925155 DOI: 10.1016/j.cca.2011.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
23 Singh SP, Barik RK. NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet? J Clin Exp Hepatol 2020;10:88-98. [PMID: 32025168 DOI: 10.1016/j.jceh.2019.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
24 Hempel F, Roderfeld M, Müntnich LJ, Albrecht J, Oruc Z, Arneth B, Karrasch T, Pons-Kühnemann J, Padberg W, Renz H, Schäffler A, Roeb E. Caspase-Cleaved Keratin 18 Measurements Identified Ongoing Liver Injury after Bariatric Surgery. J Clin Med 2021;10:1233. [PMID: 33809676 DOI: 10.3390/jcm10061233] [Reference Citation Analysis]
25 Rosso N, Stephenson AM, Giraudi PJ, Tiribelli C. Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review. Ann Transl Med 2021;9:727. [PMID: 33987425 DOI: 10.21037/atm-20-4723] [Reference Citation Analysis]
26 Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2009;25:230-237. [PMID: 19396962 DOI: 10.1097/MOG.0b013e3283294a18] [Cited by in Crossref: 54] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
27 Dyson JK, McPherson S, Anstee QM. Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgrad Med J. 2014;90:254-266. [PMID: 24737902 DOI: 10.1136/postgradmedj-2013-201620rep] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
28 Becker PP, Rau M, Schmitt J, Malsch C, Hammer C, Bantel H, Müllhaupt B, Geier A. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLoS One. 2015;10:e0142661. [PMID: 26565986 DOI: 10.1371/journal.pone.0142661] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 10.6] [Reference Citation Analysis]
29 Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60:313-326. [PMID: 21040935 DOI: 10.1016/j.metabol.2010.09.003] [Cited by in Crossref: 183] [Cited by in F6Publishing: 180] [Article Influence: 15.3] [Reference Citation Analysis]
30 Francque SM. The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. Eur Cardiol 2014;9:10-5. [PMID: 30310479 DOI: 10.15420/ecr.2014.9.1.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
31 Lomonaco R, Chen J, Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab. 2011;2:211-225. [PMID: 23148186 DOI: 10.1177/2042018811419157] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
32 Tiniakos DG. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems: . European Journal of Gastroenterology & Hepatology 2010. [DOI: 10.1097/meg.0b013e32832ca0cb] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
33 Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1. [DOI: 10.1038/nrdp.2015.80] [Cited by in Crossref: 302] [Cited by in F6Publishing: 288] [Article Influence: 43.1] [Reference Citation Analysis]
34 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
35 Tabibian JH, Lazo M, Durazo FA, Yeh HC, Tong MJ, Clark JM. Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population? J Gastroenterol Hepatol. 2011;26:501-509. [PMID: 21332546 DOI: 10.1111/j.1440-1746.2010.06443.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
36 Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013;14:20704-20728. [PMID: 24132155 DOI: 10.3390/ijms141020704] [Cited by in Crossref: 189] [Cited by in F6Publishing: 182] [Article Influence: 21.0] [Reference Citation Analysis]
37 Heeringa M, Hastings A, Yamazaki S, de Koning P. Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects? Biomark Med. 2012;6:743-757. [PMID: 23227839 DOI: 10.2217/bmm.12.87] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
38 Bedossa P, Patel K. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1811-1822.e4. [PMID: 27003601 DOI: 10.1053/j.gastro.2016.03.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
39 Razmpour F, Nematy M, Belghaisi Naseri M, Dehnavi Z, Ganji A, Vatanparast HA, Taghipour A, Azimi Nezhad M, Alamdaran SA. Which Method is Superior in the Diagnosis of Nonalcoholic Fatty Liver and Steatohepatatis in Children? Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.13584] [Reference Citation Analysis]
40 Mannery YO, McClain CJ, Vos MB. Keratin 18, Apoptosis, and Liver Disease in Children. Curr Pediatr Rev 2011;7:310-5. [PMID: 25346653 DOI: 10.2174/157339611796892364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
41 Fealy CE, Haus JM, Solomon TP, Pagadala M, Flask CA, McCullough AJ, Kirwan JP. Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) 2012;113:1-6. [PMID: 22582214 DOI: 10.1152/japplphysiol.00127.2012] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
42 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
43 Cazanave SC, Sanyal AJ. Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease. In: Ntambi JM, editor. Hepatic De Novo Lipogenesis and Regulation of Metabolism. Cham: Springer International Publishing; 2016. pp. 101-29. [DOI: 10.1007/978-3-319-25065-6_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Soga T, Sugimoto M, Honma M, Mori M, Igarashi K, Kashikura K, Ikeda S, Hirayama A, Yamamoto T, Yoshida H. Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol. 2011;55:896-905. [PMID: 21334394 DOI: 10.1016/j.jhep.2011.01.031] [Cited by in Crossref: 165] [Cited by in F6Publishing: 151] [Article Influence: 15.0] [Reference Citation Analysis]
45 Fujii H, Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol. 2012;47:215-225. [PMID: 22310735 DOI: 10.1007/s00535-012-0527-x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 9.9] [Reference Citation Analysis]
46 Blomme B, Francque S, Trépo E, Libbrecht L, Vanderschaeghe D, Verrijken A, Pattyn P, Nieuwenhove YV, Putte DV, Geerts A, Colle I, Delanghe J, Moreno C, Gaal LV, Callewaert N, Vlierberghe HV. N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. Dig Liver Dis 2012;44:315-22. [PMID: 22119618 DOI: 10.1016/j.dld.2011.10.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
47 Qiu Y, Wang S, Wan T, Ye M, Jiang R, Pei L, Yang L. Blood-based novel biomarkers for nonalcoholic steatohepatitis. Biomark Med 2018;12:501-15. [PMID: 29712439 DOI: 10.2217/bmm-2017-0361] [Reference Citation Analysis]
48 Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol 2017; 8(2): 11-26 [PMID: 28573064 DOI: 10.4291/wjgp.v8.i2.11] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 9.4] [Reference Citation Analysis]
49 Yilmaz Y, Eren F. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2014;26:1292-5. [DOI: 10.1097/meg.0000000000000184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
50 Yilmaz Y, Eren F. Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. Clin Chim Acta 2012;414:154-7. [PMID: 22985537 DOI: 10.1016/j.cca.2012.08.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
51 Sekiguchi T, Umemura T, Fujimori N, Shibata S, Ichikawa Y, Kimura T, Joshita S, Komatsu M, Matsumoto A, Tanaka E, Ota M. Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis. PLoS One 2015;10:e0131658. [PMID: 26110613 DOI: 10.1371/journal.pone.0131658] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
52 Feldstein AE, Nobili V. Biomarkers in nonalcoholic fatty liver disease: a new era in diagnosis and staging of disease in children. J Pediatr Gastroenterol Nutr 2010;51:378-9. [PMID: 20808243 DOI: 10.1097/MPG.0b013e3181ecf3d4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
53 Casoinic F, Sampelean D, Buzoianu AD, Hancu N, Baston D. Serum Levels of Oxidative Stress Markers in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Steatohepatitis. Rom J Intern Med 2016;54:228-36. [PMID: 28002036 DOI: 10.1515/rjim-2016-0035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
54 Schneck AS, Anty R, Patouraux S, Bonnafous S, Rousseau D, Lebeaupin C, Bailly-Maitre B, Sans A, Tran A, Gugenheim J, Iannelli A, Gual P. Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis. Front Physiol. 2016;7:344. [PMID: 27594839 DOI: 10.3389/fphys.2016.00344] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
55 He L, Deng L, Zhang Q, Guo J, Zhou J, Song W, Yuan F. Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Biomed Res Int. 2017;2017:9729107. [PMID: 28326329 DOI: 10.1155/2017/9729107] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
56 Doherty DT, Coe PO, Rimmer L, Lapsia S, Krige A, Subar DA. Hepatic steatosis in patients undergoing resection of colorectal liver metastases: A target for prehabilitation? A narrative review. Surg Oncol 2019;30:147-58. [PMID: 31471139 DOI: 10.1016/j.suronc.2019.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Arulanandan A, Loomba R. Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet? Curr Hepatol Rep 2015;14:109-18. [PMID: 26500833 DOI: 10.1007/s11901-015-0263-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
58 Zhang ZB, Sun XQ, Qian F, Xue BY. Role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2011; 19(19): 2036-2042 [DOI: 10.11569/wcjd.v19.i19.2036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Annals of Hepatology 2009;8:S51-9. [DOI: 10.1016/s1665-2681(19)31827-7] [Cited by in Crossref: 26] [Article Influence: 2.0] [Reference Citation Analysis]
60 Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, Manns MP, Schulze-osthoff K, Bantel H. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012;55:455-64. [DOI: 10.1002/hep.24734] [Cited by in Crossref: 125] [Cited by in F6Publishing: 112] [Article Influence: 11.4] [Reference Citation Analysis]
61 Tannapfel A, Denk H, Dienes H, Langner C, Schirmacher P, Trauner M, Flott-rahmel B. Histopathologische Diagnose der nichtalkoholischen und alkoholischen Fettlebererkrankung: Konsensusbasierte Leitlinie der Stufe 2. Pathologe 2010;31:225-37. [DOI: 10.1007/s00292-010-1274-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
62 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch. 2011;458:511-523. [PMID: 21442288 DOI: 10.1007/s00428-011-1066-1].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Lee YS, Lee JE, Yi HS, Jung YK, Jun DW, Kim JH, Seo YS, Yim HJ, Kim BH, Kim JW, Lee CH, Yeon JE, Lee J, Um SH, Byun KS. MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatol Int 2022. [PMID: 35254642 DOI: 10.1007/s12072-022-10300-3] [Reference Citation Analysis]
64 Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. Diabetes Metab J. 2019;43:31-45. [PMID: 30793550 DOI: 10.4093/dmj.2019.0011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 20.0] [Reference Citation Analysis]
65 Li F, Cousineau C, Xing G, Raha N, Clemens S, Mofikoya M, Kim MY, Zhang JY. Development and validation of a quantitative ultra performance LC® hydrophilic interaction liquid chromatography MS/MS method to measure fructose and sorbitol in human plasma. Bioanalysis 2019;11:407-25. [PMID: 30887836 DOI: 10.4155/bio-2018-0286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Culafic M, Vezmar Kovacevic S, Dopsaj V, Stulic M, Vlaisavljevic Z, Miljkovic B, Culafic D. A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests. Medicina (Kaunas). 2019;55. [PMID: 31163711 DOI: 10.3390/medicina55060243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
67 Hyysalo J, Männistö VT, Zhou Y, Arola J, Kärjä V, Leivonen M, Juuti A, Jaser N, Lallukka S, Käkelä P. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol. 2014;60:839-846. [PMID: 24333862 DOI: 10.1016/j.jhep.2013.12.009] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 8.4] [Reference Citation Analysis]
68 Noureddin M, Loomba R. Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers. Clin Liver Dis (Hoboken) 2012;1:104-7. [PMID: 31186861 DOI: 10.1002/cld.65] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
69 Oh H, Jun DW, Saeed WK, Nguyen MH. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. Clin Mol Hepatol. 2016;22:327-335. [PMID: 27729634 DOI: 10.3350/cmh.2016.0049] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
70 Gatselis NK, Ntaios G, Makaritsis K, Dalekos GN. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med. 2014;14:121-131. [PMID: 23292294 DOI: 10.1007/s10238-012-0227-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
71 Ulukaya S, Ulukaya E, Alper I, Yilmaztepe-Oral A, Kilic M. Soluble cytokeratin 18 biomarkers may provide information on the type of cell death during early ischemia and reperfusion periods of liver transplantation. Clin Transplant 2010;24:848-54. [PMID: 20030677 DOI: 10.1111/j.1399-0012.2009.01177.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
72 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 178] [Article Influence: 16.3] [Reference Citation Analysis]
73 Ratziu V, Martin L, Fedchuk L, Poynard T. Can nonalcoholic steatohepatitis be diagnosed without liver biopsy? Biomark Med 2009;3:353-61. [PMID: 20477484 DOI: 10.2217/bmm.09.36] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
74 Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013;37:392-400. [PMID: 23278163 DOI: 10.1111/apt.12186] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 11.3] [Reference Citation Analysis]
75 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
76 Potoupni V, Georgiadou M, Chatzigriva E, Polychronidou G, Markou E, Zapantis Gakis C, Filimidou I, Karagianni M, Anastasilakis D, Evripidou K, Ftergioti A, Togkaridou M, Tsaftaridis N, Apostolopoulos A, Polyzos SA. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34289181 DOI: 10.1111/jgh.15631] [Reference Citation Analysis]
77 Verhaegh P, Bavalia R, Winkens B, Masclee A, Jonkers D, Koek G. Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2018;16:837-61. [DOI: 10.1016/j.cgh.2017.08.024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
78 Rabelo F, Oliveira CPMS, Faintuch J, Mazo DFC, Lima VMR, Stefano JT, Barbeiro HV, Soriano FG, Alves VAF, Carrilho FJ. Pro- and Anti-inflammatory Cytokines in Steatosis and Steatohepatitis. OBES SURG 2010;20:906-12. [DOI: 10.1007/s11695-010-0181-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
79 Pimentel CF, Jiang ZG, Otsubo T, Feldbrügge L, Challies TL, Nasser I, Robson S, Afdhal N, Lai M. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci 2016;61:905-12. [PMID: 26462489 DOI: 10.1007/s10620-015-3916-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
80 Balmer ML, Joneli J, Schoepfer A, Stickel F, Thormann W, Dufour JF. Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond). 2010;119:431-436. [PMID: 20524936 DOI: 10.1042/cs20100008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
81 Marques V, Afonso MB, Bierig N, Duarte-Ramos F, Santos-Laso Á, Jimenez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Luís R, Costa A, Machado MV, Alonso C, Arretxe E, Alustiza JM, Krawczyk M, Lammert F, Tiniakos DG, Flehmig B, Cortez-Pinto H, Banales JM, Castro RE, Normann A, Rodrigues CMP. Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. Front Med (Lausanne) 2021;8:683250. [PMID: 34249975 DOI: 10.3389/fmed.2021.683250] [Reference Citation Analysis]
82 Lavallard VJ, Bonnafous S, Patouraux S, Saint-Paul MC, Rousseau D, Anty R, Le Marchand-Brustel Y, Tran A, Gual P. Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLoS One. 2011;6:e17599. [PMID: 21445263 DOI: 10.1371/journal.pone.0017599] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
83 Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73:1-14. [PMID: 23329465 DOI: 10.1007/s40265-012-0004-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 11.7] [Reference Citation Analysis]
84 Maliken BD, Nelson JE, Klintworth HM, Beauchamp M, Yeh MM, Kowdley KV. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology. 2013;57:1806-1813. [PMID: 23325576 DOI: 10.1002/hep.26238] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
85 Lee J, Vali Y, Boursier J, Duffin K, Verheij J, Brosnan MJ, Zwinderman K, Anstee QM, Bossuyt PM, Zafarmand MH. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLoS One 2020;15:e0238717. [PMID: 32915852 DOI: 10.1371/journal.pone.0238717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
86 Yang M, Xu D, Liu Y, Guo X, Li W, Guo C, Zhang H, Gao Y, Mao Y, Zhao J. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. PLoS One. 2015;10:e0131664. [PMID: 26121037 DOI: 10.1371/journal.pone.0131664] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
87 Myers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. Annals of Hepatology 2009;8:S25-33. [DOI: 10.1016/s1665-2681(19)31823-x] [Cited by in Crossref: 27] [Article Influence: 2.1] [Reference Citation Analysis]
88 Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-58. [PMID: 22446927 DOI: 10.1016/j.cgh.2012.03.011] [Cited by in Crossref: 156] [Cited by in F6Publishing: 142] [Article Influence: 15.6] [Reference Citation Analysis]
89 Younossi ZM, Baranova A, Stepanova M, Page S, Calvert VS, Afendy A, Goodman Z, Chandhoke V, Liotta L, Petricoin E. Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. J Proteome Res 2010;9:3218-24. [PMID: 20441224 DOI: 10.1021/pr100069e] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
90 Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254-269. [PMID: 24308774 DOI: 10.1111/apt.12569] [Cited by in Crossref: 228] [Cited by in F6Publishing: 197] [Article Influence: 25.3] [Reference Citation Analysis]
91 Torruellas C, French SW, Medici V. Diagnosis of alcoholic liver disease. World J Gastroenterol 2014; 20(33): 11684-11699 [PMID: 25206273 DOI: 10.3748/wjg.v20.i33.11684] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
92 Bril F, Lomonaco R, Orsak B, Ortiz-Lopez C, Webb A, Tio F, Hecht J, Cusi K. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology. 2014;59:2178-2187. [PMID: 24777953 DOI: 10.1002/hep.26988] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 10.1] [Reference Citation Analysis]
93 Colak Y, Senates E, Ozturk O, Yilmaz Y, Zemheri E, Yilmaz Enc F, Ulasoglu C, Aksaray S, Bozbeyoglu SG, Kiziltas S, Kurdas OO, Tuncer I. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol 2012;24:255-61. [PMID: 22157234 DOI: 10.1097/MEG.0b013e32834e8041] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
94 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 605] [Article Influence: 53.1] [Reference Citation Analysis]
95 Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50:1072-1078. [PMID: 19585618 DOI: 10.1002/hep.23050] [Cited by in Crossref: 450] [Cited by in F6Publishing: 403] [Article Influence: 34.6] [Reference Citation Analysis]
96 Amacher DE. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease. Biomarkers 2014;19:541-52. [PMID: 25189636 DOI: 10.3109/1354750X.2014.958535] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
97 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch. 2011;458:511-523. [PMID: 21442288 DOI: 10.1007/s00428-011-1066-1] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 6.3] [Reference Citation Analysis]
98 Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH. Dig Dis 2011;29:202-10. [PMID: 21734385 DOI: 10.1159/000323886] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
99 Kupčová V, Fedelešová M, Bulas J, Kozmonová P, Turecký L. Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. Int J Environ Res Public Health 2019;16:E3570. [PMID: 31554274 DOI: 10.3390/ijerph16193570] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
100 Ratziu V, Sheikh MY, Sanyal AJ, Lim JK, Conjeevaram H, Chalasani N, Abdelmalek M, Bakken A, Renou C, Palmer M, Levine RA, Bhandari BR, Cornpropst M, Liang W, King B, Mondou E, Rousseau FS, McHutchison J, Chojkier M. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology. 2012;55:419-428. [PMID: 22006541 DOI: 10.1002/hep.24747] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 10.9] [Reference Citation Analysis]
101 Wu XX, Zheng KI, Boursier J, Chan WK, Yilmaz Y, Romero-Gómez M, El Kassas M, Targher G, Byrne CD, Huang ZM, Zheng MH. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. EClinicalMedicine 2021;41:101145. [PMID: 34646997 DOI: 10.1016/j.eclinm.2021.101145] [Reference Citation Analysis]
102 Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016;65:1062-79. [DOI: 10.1016/j.metabol.2015.11.006] [Cited by in Crossref: 147] [Cited by in F6Publishing: 138] [Article Influence: 24.5] [Reference Citation Analysis]
103 Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther. 2009;30:1103-1109. [PMID: 19769633 DOI: 10.1111/j.1365-2036.2009.04148.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 4.8] [Reference Citation Analysis]
104 Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48:97-113. [PMID: 21875310 DOI: 10.3109/10408363.2011.596521] [Cited by in Crossref: 183] [Cited by in F6Publishing: 171] [Article Influence: 16.6] [Reference Citation Analysis]
105 Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res. 2013;1:7. [PMID: 24252302 DOI: 10.1186/2050-7771-1-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
106 Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens). 2012;11:8-20. [PMID: 22450341 DOI: 10.1007/bf03401534] [Cited by in Crossref: 153] [Cited by in F6Publishing: 79] [Article Influence: 15.3] [Reference Citation Analysis]
107 Ratziu V, Caldwell S, Neuschwander-tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues. Hepatology 2010;52:2206-15. [DOI: 10.1002/hep.24042] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 4.3] [Reference Citation Analysis]
108 Yoshimura K, Okanoue T, Ebise H, Iwasaki T, Mizuno M, Shima T, Ichihara J, Yamazaki K. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology 2016;63:462-73. [PMID: 26390046 DOI: 10.1002/hep.28226] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
109 Luo Y, Oseini A, Gagnon R, Charles ED, Sidik K, Vincent R, Collen R, Idowu M, Contos MJ, Mirshahi F, Daita K, Asgharpour A, Siddiqui MS, Jarai G, Rosen G, Christian R, Sanyal AJ. An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis. Sci Rep. 2018;8:12414. [PMID: 30120271 DOI: 10.1038/s41598-018-30457-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
110 Tsai E, Lee TP. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2018;22:73-92. [PMID: 29128062 DOI: 10.1016/j.cld.2017.08.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
111 Hashimoto E, Farrell GC. Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis? J Gastroenterol Hepatol. 2009;24:501-503. [PMID: 19368628 DOI: 10.1111/j.1440-1746.2009.05806.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
112 Shen J, Chan HL, Wong GL, Chan AW, Choi PC, Chan HY, Chim AM, Yeung DK, Yu J, Chu WC. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment Pharmacol Ther. 2012;36:1057-1066. [PMID: 23066946 DOI: 10.1111/apt.12091] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
113 Polyzos SA, Kountouras J, Zavos C. Nonlinear Distribution of Adiponectin in Patients With Nonalcoholic Fatty Liver Disease Limits Its Use in Linear Regression Analysis. Journal of Clinical Gastroenterology 2010;44:229-30. [DOI: 10.1097/mcg.0b013e3181b5ce68] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
114 Henry ZH, Argo CK. How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. Gastroenterology Clinics of North America 2020;49:45-62. [DOI: 10.1016/j.gtc.2019.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
115 Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Review of Gastroenterology & Hepatology 2014;5:189-200. [DOI: 10.1586/egh.11.21] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
116 Miller MH, Ferguson MAJ, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease: Performance of non-invasive biomarkers in non-alcoholic fatty liver disease. Liver International 2011;31:461-73. [DOI: 10.1111/j.1478-3231.2011.02451.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
117 Talwalkar JA. One step at a time: identification and validation of biomarkers for nonalcoholic steatohepatitis. Hepatology 2009;50:1000-3. [PMID: 19787817 DOI: 10.1002/hep.23288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
118 Leal VDO, Mafra D. Adipokines in obesity. Clinica Chimica Acta 2013;419:87-94. [DOI: 10.1016/j.cca.2013.02.003] [Cited by in Crossref: 151] [Cited by in F6Publishing: 127] [Article Influence: 16.8] [Reference Citation Analysis]
119 Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells 2020;9:E1005. [PMID: 32316690 DOI: 10.3390/cells9041005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
120 Ismaiel A, Leucuta DC, Popa SL, Dumitrascu DL. Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis. J Clin Med 2021;10:3029. [PMID: 34300193 DOI: 10.3390/jcm10143029] [Reference Citation Analysis]
121 Prysyazhnyuk VP, Rossokha ZI, Gorovenko NG. Variation in particular biochemical indicators, cytokine and adipokine profiles of the blood, and the structural and functional parameters of the liver in patients with nonalcoholic fatty liver disease and different genotypes by the polymorphic locus A313G of the GSTP1 gene. Cytol Genet 2017;51:455-61. [DOI: 10.3103/s0095452717060111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
122 Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int. 2010;30:795-808. [PMID: 20624207 DOI: 10.1111/j.1478-3231.2010.02264.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
123 Simo KA, McKillop IH, McMillan MT, Ahrens WA, Walters AL, Thompson KJ, Kuwada TS, Martinie JB, Iannitti DA, Gersin KS, Sindram D. Does a calculated "NAFLD fibrosis score" reliably negate the need for liver biopsy in patients undergoing bariatric surgery? Obes Surg. 2014;24:15-21. [PMID: 23934335 DOI: 10.1007/s11695-013-1044-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
124 Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, Ortiz-Lopez C, Hecht J, Feldstein AE, Webb A, Louden C, Goros M, Tio F. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60:167-174. [PMID: 23973932 DOI: 10.1016/j.jhep.2013.07.042] [Cited by in Crossref: 154] [Cited by in F6Publishing: 138] [Article Influence: 17.1] [Reference Citation Analysis]
125 Yilmaz Y, Dolar E. Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or decorations? World J Gastroenterol 2009; 15(34): 4346-4347 [PMID: 19750583 DOI: 10.3748/wjg.15.4346] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
126 Abenavoli L, Milic N, Di Renzo L, Preveden T, Medić-Stojanoska M, De Lorenzo A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22(31): 7006-7016 [PMID: 27610012 DOI: 10.3748/wjg.v22.i31.7006] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 94] [Article Influence: 16.3] [Reference Citation Analysis]
127 Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010;12:365-383. [PMID: 20415685 DOI: 10.1111/j.1463-1326.2009.01176.x] [Cited by in Crossref: 142] [Cited by in F6Publishing: 138] [Article Influence: 12.9] [Reference Citation Analysis]
128 Argentou M, Tiniakos DG, Karanikolas M, Melachrinou M, Makri MG, Kittas C, Kalfarentzos F. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg. 2009;19:1313-1323. [PMID: 19693638 DOI: 10.1007/s11695-009-9912-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
129 Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: REVIEW: CURRENT MANAGEMENT OF NAFLD AND NASH. Alimentary Pharmacology & Therapeutics 2008;28:2-12. [DOI: 10.1111/j.1365-2036.2008.03710.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 7.2] [Reference Citation Analysis]
130 Cengiz M, Ozenirler S, Elbeg S. Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis. J Gastroenterol Hepatol. 2015;30:1190-1196. [PMID: 25684563 DOI: 10.1111/jgh.12924] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
131 Cao W, Zhao C, Shen C, Wang Y. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis. PLoS One 2013;8:e82092. [PMID: 24324749 DOI: 10.1371/journal.pone.0082092] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
132 Yilmaz Y, Kedrah AE, Ozdogan O. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol 2009; 15(35): 4387-4391 [PMID: 19764089 DOI: 10.3748/wjg.15.4387] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
133 Dyson JK, Mcpherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013;66:1033-45. [DOI: 10.1136/jclinpath-2013-201620] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
134 Edwards CR, Hindle AK, Latham PS, Fu SW, Brody FJ. Resistin expression correlates with steatohepatitis in morbidly obese patients. Surg Endosc. 2013;27:1310-1314. [PMID: 23233000 DOI: 10.1007/s00464-012-2603-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
135 Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016;17:68-80. [PMID: 26597657 DOI: 10.1111/obr.12333] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
136 Le Corvec M, Allain C, Lardjane S, Cavey T, Turlin B, Fautrel A, Begriche K, Monbet V, Fromenty B, Leroyer P, Guggenbuhl P, Ropert M, Sire O, Loréal O. Mid-infrared fibre evanescent wave spectroscopy of serum allows fingerprinting of the hepatic metabolic status in mice. Analyst 2016;141:6259-69. [DOI: 10.1039/c6an00136j] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
137 Amirkalali B, Sohrabi MR, Gholami A, Hosseinzadeh P, Shidfar F, Zamani F. Interpretation of Serum Visfatin Level in Relation to Hepatic Injury is Probably Gender Dependent in Nonalcoholic Fatty Liver Disease. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.13242] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
138 Pan Q, Fan JG. Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. Hepatobiliary Pancreat Dis Int 2019;18:1-3. [PMID: 30611667 DOI: 10.1016/j.hbpd.2018.12.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008;48:2086-7; author reply 2087. [PMID: 19030167 DOI: 10.1002/hep.22622] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
140 Abdel-Razik A, Mousa N, Shabana W, Refaey M, Elzehery R, Elhelaly R, Zalata K, Abdelsalam M, Eldeeb AA, Awad M, Elgamal A, Attia A, El-Wakeel N, Eldars W. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot. Eur J Gastroenterol Hepatol. 2018;30:1237-1246. [PMID: 30096092 DOI: 10.1097/meg.0000000000001232] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
141 Eng K, Lopez R, Liccardo D, Nobili V, Alkhouri N. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease. Dig Liver Dis 2014;46:1008-13. [PMID: 25106814 DOI: 10.1016/j.dld.2014.07.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
142 Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol. 2013;23:483-491. [PMID: 23876851 DOI: 10.1016/j.semcancer.2013.07.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]
143 Poynard T, Imbert-bismut F. Laboratory Testing for Liver Disease. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 201-15. [DOI: 10.1016/b978-1-4377-0881-3.00014-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Chakraborty JB, Oakley F, Walsh MJ. Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Int J Hepatol. 2012;2012:648915. [PMID: 22567408 DOI: 10.1155/2012/648915] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 6.6] [Reference Citation Analysis]
145 Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol. 2010;4:623-635. [PMID: 20932147 DOI: 10.1586/egh.10.56] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
146 Cengiz M, Ozenirler S. Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:1293-1299. [PMID: 26302023 DOI: 10.1097/meg.0000000000000445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
147 Francque SM, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, Michielsen P, Van Gaal L. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol. 2012;10:1162-1168; quiz e87. [PMID: 22796457 DOI: 10.1016/j.cgh.2012.06.019] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
148 Cai W, Song JM, Rexiti M, Wang LF, Guo ZS, Li G, Ding Y, Yao H. Association of serum CK18-M65 and -M30 with non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2013; 21(24): 2378-2384 [DOI: 10.11569/wcjd.v21.i24.2378] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Machado MV, Coutinho J, Carepa F, Costa A, Proença H, Cortez-pinto H. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease: . European Journal of Gastroenterology & Hepatology 2012;24:1166-72. [DOI: 10.1097/meg.0b013e32835609b0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
150 Hernandez Roman J, Siddiqui MS. The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. Endocrinol Diabetes Metab 2020;3:e00127. [PMID: 33102796 DOI: 10.1002/edm2.127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
151 Di Mauro S, Scamporrino A, Filippello A, Di Pino A, Scicali R, Malaguarnera R, Purrello F, Piro S. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. Int J Mol Sci 2021;22:11905. [PMID: 34769333 DOI: 10.3390/ijms222111905] [Reference Citation Analysis]
152 Yilmaz Y, Kurt R, Kalayci C. Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments. Biomarkers in Medicine 2010;4:743-5. [DOI: 10.2217/bmm.10.65] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
153 Kim CW, Lee CD. Apoptosis and diagnosis of nonalcoholic steatohepatitis. Korean J Hepatol 2011;17:247-9. [PMID: 22102395 DOI: 10.3350/kjhep.2011.17.3.247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Tamimi TI, Elgouhari HM, Alkhouri N, Yerian LM, Berk MP, Lopez R, Schauer PR, Zein NN, Feldstein AE. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol. 2011;54:1224-1229. [PMID: 21145805 DOI: 10.1016/j.jhep.2010.08.023] [Cited by in Crossref: 115] [Cited by in F6Publishing: 103] [Article Influence: 10.5] [Reference Citation Analysis]
155 Hegazy M, Abo-Elfadl S, Mostafa A, Ibrahim M, Rashed L, Salman A. Serum Resistin Level and Its Receptor Gene Expression in Liver Biopsy as Predictors for the Severity of Nonalcoholic Fatty Liver Disease. Euroasian J Hepatogastroenterol 2014;4:59-62. [PMID: 29699348 DOI: 10.5005/jp-journals-10018-1102i] [Reference Citation Analysis]
156 Perakakis N, Polyzos SA, Yazdani A, Sala-Vila A, Kountouras J, Anastasilakis AD, Mantzoros CS. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism 2019;101:154005. [PMID: 31711876 DOI: 10.1016/j.metabol.2019.154005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 13.0] [Reference Citation Analysis]
157 Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Int J Endocrinol 2015;2015:343828. [PMID: 26064107 DOI: 10.1155/2015/343828] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
158 Yilmaz Y. “Defragmenting” the noninvasive diagnosis of nonalcoholic steatohepatitis: Hopes from cytokeratin-18. Hepatology 2009;50:990-1. [DOI: 10.1002/hep.23065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
159 Kremer AE, Rust C, Eichhorn P, Beuers U, Holdenrieder S. Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers. Expert Rev Mol Diagn 2009;9:139-56. [PMID: 19298138 DOI: 10.1586/14737159.9.2.139] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
160 Widhalm K, Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes 2010;34:1451-67. [DOI: 10.1038/ijo.2010.185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
161 Prysyazhnyuk V, Sydorchuk L, Sydorchuk R, Prysiazhniuk I, Bobkovych K, Buzdugan I, Dzuryak V, Prysyazhnyuk P. Glutathione-S-transferases genes-promising predictors of hepatic dysfunction. World J Hepatol 2021; 13(6): 620-633 [PMID: 34239698 DOI: 10.4254/wjh.v13.i6.620] [Reference Citation Analysis]
162 Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, Afendy A, Younoszai Z, Goodman Z, Baranova A. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg. 2011;21:431-439. [PMID: 20532833 DOI: 10.1007/s11695-010-0204-1] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 9.5] [Reference Citation Analysis]
163 Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology. 2013;57:103-111. [PMID: 22930399 DOI: 10.1002/hep.26030] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 8.1] [Reference Citation Analysis]
164 Zhao J, Hu Y, Peng J. Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy. Cell Mol Biol Lett 2021;26:17. [PMID: 33962586 DOI: 10.1186/s11658-021-00254-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
165 Moschen AR, Molnar C, Wolf AM, Weiss H, Graziadei I, Kaser S, Ebenbichler CF, Stadlmann S, Moser PL, Tilg H. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol. 2009;51:765-777. [PMID: 19664840 DOI: 10.1016/j.jhep.2009.06.016] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 6.7] [Reference Citation Analysis]
166 Adams LA, Feldstein AE. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J Dig Dis. 2011;12:10-16. [PMID: 21091933 DOI: 10.1111/j.1751-2980.2010.00471.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
167 Yilmaz Y, Ulukaya E, Dolar E. A “Biomarker Biopsy” for the Diagnosis of NASH: Promises from CK-18 Fragments. OBES SURG 2008;18:1507-8. [DOI: 10.1007/s11695-008-9639-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
168 Han D, Chen J, Liu S, Zhang Z, Zhao Z, Jin W, Xin Y. Serum Resistin Levels in Adult Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. J Clin Transl Hepatol 2021;9:484-93. [PMID: 34447677 DOI: 10.14218/JCTH.2021.00018] [Reference Citation Analysis]
169 Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res 2014;44:854-62. [PMID: 23834322 DOI: 10.1111/hepr.12197] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
170 Segura-Azuara NLÁ, Varela-Chinchilla CD, Trinidad-Calderón PA. MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis. Front Med (Lausanne) 2021;8:774079. [PMID: 35096868 DOI: 10.3389/fmed.2021.774079] [Reference Citation Analysis]
171 Yu C, Xu C, Xu L, Yu J, Miao M, Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol. 2012;56:241-247. [PMID: 21756851 DOI: 10.1016/j.jhep.2011.05.027] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
172 Wang Y, Zhou M, Lam KS, Xu A. Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. Arq Bras Endocrinol Metabol 2009;53:201-12. [PMID: 19466213 DOI: 10.1590/s0004-27302009000200012] [Cited by in Crossref: 56] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
173 Alkhouri N, Carter-Kent C, Feldstein AE. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol 2011;5:201-12. [PMID: 21476915 DOI: 10.1586/egh.11.6] [Cited by in Crossref: 134] [Cited by in F6Publishing: 134] [Article Influence: 12.2] [Reference Citation Analysis]
174 Maher MM, Ibrahim WA, Saleh SA, Shash L, Abou Gabal H, Tarif M, Gamal M. Cytokeratin 18 as a non invasive marker in diagnosis of NASH and its usefulness in correlation with disease severity in Egyptian patients. Egyptian Journal of Medical Human Genetics 2015;16:41-6. [DOI: 10.1016/j.ejmhg.2014.11.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
175 Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156:1264-1281.e4. [PMID: 30660725 DOI: 10.1053/j.gastro.2018.12.036] [Cited by in Crossref: 310] [Cited by in F6Publishing: 296] [Article Influence: 103.3] [Reference Citation Analysis]
176 Nazal L, Riquelme A, Solís N, Pizarro M, Escalona A, Burotto M, Méndez JI, Saint-Jean C, Concha MJ, Giovanni S. Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients. Obes Surg. 2010;20:1400-1407. [PMID: 20066503 DOI: 10.1007/s11695-009-0051-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
177 Ku NO, Strnad P, Bantel H, Omary MB. Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology 2016;64:966-76. [PMID: 26853542 DOI: 10.1002/hep.28493] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 9.3] [Reference Citation Analysis]
178 Ramai D, Facciorusso A, Vigandt E, Schaf B, Saadedeen W, Chauhan A, di Nunzio S, Shah A, Giacomelli L, Sacco R. Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Cells 2021;10:3401. [PMID: 34943908 DOI: 10.3390/cells10123401] [Reference Citation Analysis]
179 Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617-649. [PMID: 21039302 DOI: 10.3109/07853890.2010.518623] [Cited by in Crossref: 770] [Cited by in F6Publishing: 699] [Article Influence: 64.2] [Reference Citation Analysis]
180 Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol 2014; 20(31): 10851-10863 [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 59] [Article Influence: 8.5] [Reference Citation Analysis]
181 Zhang AR, Sun J, He Y, Wang N, Tian L. Attenuation of lipid accumulation in Bel-7402 cells through ADPN/AMPKα signaling stimulated by Fructus rosae laxae extract. J Food Biochem 2020;44:e13497. [PMID: 33029846 DOI: 10.1111/jfbc.13497] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
182 Hagymási K, Lengyel G. Non-alcoholic steatosis/steatohepatitis – 2010. Orvosi Hetilap 2010;151:1940-5. [DOI: 10.1556/oh.2010.28989] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
183 Gautheron J, Vucur M, Reisinger F, Cardenas DV, Roderburg C, Koppe C, Kreggenwinkel K, Schneider AT, Bartneck M, Neumann UP. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med. 2014;6:1062-1074. [PMID: 24963148 DOI: 10.15252/emmm.201403856] [Cited by in Crossref: 163] [Cited by in F6Publishing: 156] [Article Influence: 23.3] [Reference Citation Analysis]
184 Anty R, Iannelli A, Patouraux S, Bonnafous S, Lavallard VJ, Senni-Buratti M, Amor IB, Staccini-Myx A, Saint-Paul MC, Berthier F, Huet PM, Le Marchand-Brustel Y, Gugenheim J, Gual P, Tran A. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther. 2010;32:1315-1322. [PMID: 21050233 DOI: 10.1111/j.1365-2036.2010.04480.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 7.7] [Reference Citation Analysis]
185 Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58:1007-1019. [PMID: 23183525 DOI: 10.1016/j.jhep.2012.11.021] [Cited by in Crossref: 237] [Cited by in F6Publishing: 203] [Article Influence: 23.7] [Reference Citation Analysis]
186 Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2008;19:371-379. [PMID: 18929493 DOI: 10.1016/j.tem.2008.08.005] [Cited by in Crossref: 288] [Cited by in F6Publishing: 280] [Article Influence: 20.6] [Reference Citation Analysis]